Business Context and Reporting Period
Company: Dermata Therapeutics, Inc. (DRMA)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2025
Business Overview: Dermata is a development-stage biotechnology company. In September 2025, management executed a strategic pivot from pursuing prescription (Rx) drug approval for its lead candidate, XYNGARI, to developing and distributing Over-The-Counter (OTC) pharmaceutical dermatology products. The company plans to launch its first OTC acne kit in mid-2026.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(1,691,989) | $(3,173,156) | $(5,696,669) | $(9,136,523) |
| Operating Expenses | $1,760,671 | $3,225,653 | $5,873,205 | $9,312,954 |
| Cash and Equivalents (End of Period) | $4,664,127 (as of Sept 30, 2025) | |||
| Accumulated Deficit | $(71,372,008) (as of Sept 30, 2025) | |||
| Net Cash Used in Operating Activities (YTD) | $(6,428,362) | $(8,249,334) | ||
| Net Cash Provided by Financing Activities (YTD) | $7,930,919 | $6,954,951 |
Liquidity: As of September 30, 2025, the company held $4.7 million in cash. Management estimates this will fund operations into the second quarter of 2026. The filing includes a "Going Concern" warning due to recurring losses and the need for additional capital.
Material Changes vs. Prior Period
- Strategic Pivot: The company withdrew its Investigational New Drug (IND) application for XYNGARI (Rx) to focus on OTC products, significantly altering its development roadmap and expense profile.
- Expense Reduction: Research and Development (R&D) expenses decreased by $1.9 million in Q3 2025 compared to Q3 2024, primarily due to the completion of the Phase 3 STAR-1 clinical trial in Q2 2025.
- Marketing Increase: Selling, General, and Administrative (SG&A) expenses increased by $0.4 million in Q3 2025, driven by $0.5 million in marketing expenses related to the upcoming OTC product launch.
- Capital Raises: The company raised approximately $7.9 million in net proceeds during the first nine months of 2025 through a January 2025 PIPE ($2.2 million) and a March 2025 Warrant Inducement ($5.7 million).
- Reverse Stock Split: A 1-for-10 reverse stock split was effected on August 1, 2025. All share and per-share data in the filing have been retroactively adjusted.
Outlook, Risks, and Contingencies
- Product Launch: The company targets a mid-2026 launch of a topical acne kit combining Spongilla technology with an FDA OTC monograph active ingredient (salicylic acid).
- Going Concern: Substantial doubt exists regarding the company's ability to continue as a going concern for one year from the filing date without additional financing.
- Legal Dispute (Villani, Inc.): On November 10, 2025, the licensor of the company's core Spongilla technology, Villani, Inc., issued a notice of material breach. Villani alleges the company failed to pursue a prescription business and that the new OTC kits do not qualify as licensed products. Villani has requested the reversion of assets and preservation of inventory. The company disputes these claims, and the outcome is uncertain.
- Supply Chain Risk: The company relies on an exclusive supply agreement with a Russian entity for Spongilla raw material. U.S. sanctions and export controls pose a risk to future supply.
- Regulatory Risk: Transitioning to OTC monograph pathways carries risks of FDA enforcement if the product formulation or labeling does not strictly comply with monograph conditions.
Investor Verification Checklist
- License Dispute Status: Verify the current status of the dispute with Villani, Inc., as a loss of the Spongilla license would be existential to the business.
- Cash Runway: Confirm the accuracy of the "second quarter 2026" cash runway estimate given the increased marketing spend for the OTC launch.
- OTC Regulatory Path: Assess the specific FDA OTC monograph requirements for the proposed acne kit and the risk of the FDA classifying Spongilla as an active ingredient requiring a New Drug Application (NDA).
- Supply Chain Resilience: Investigate the company's contingency plans for sourcing Spongilla raw material given the Russian supplier and ongoing geopolitical sanctions.
- Related Party Transactions: Review the $0.5 million marketing agreement with Wilder & Partners, LLC, where the founding partner is the CEO's son-in-law.